Free tool
FAERS Monitor: Xuriden
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208169 or its brand name (Xuriden, Uridine Triacetate). Reports on generic versions are filed under their own applications.
Reports
48
Serious
28
58% of reports
Hospitalization
17
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use11
- diarrhoea4
- foetal exposure during pregnancy4
- low birth weight baby4
- mucosal inflammation4
- premature baby4
- thrombocytopenia4
- asthenia3
- drug ineffective3
- drug ineffective for unapproved indication3
- dysphagia3
- gastroenteritis3
- neutropenia3
- neutropenic colitis3
- stomatitis3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,111 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutropenic colitisSignal | 3 | 636.6 | 212.6 | 1,319 |
| low birth weight babySignal | 4 | 220.7 | 86.3 | 669 |
| gastroenteritisSignal | 3 | 90.1 | 30.1 | 183 |
| mucosal inflammationSignal | 4 | 67.0 | 26.2 | 198 |
| premature babySignal | 4 | 58.2 | 22.8 | 172 |
| drug ineffective for unapproved indicationSignal | 3 | 24.0 | 8.0 | 45 |
| stomatitisSignal | 3 | 21.7 | 7.2 | 40 |
| foetal exposure during pregnancySignal | 4 | 21.6 | 8.4 | 59 |
| thrombocytopeniaSignal | 4 | 15.7 | 6.1 | 41 |
| dysphagiaSignal | 3 | 13.8 | 4.6 | 24 |
| neutropeniaSignal | 3 | 9.7 | 3.2 | 16 |
| off label useSignal | 11 | 5.5 | 3.3 | 38 |
| asthenia | 3 | 3.5 | 1.2 | 3 |
| diarrhoea | 4 | 2.7 | 1.1 | 3 |
| drug ineffective | 3 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.